tiprankstipranks
Advertisement
Advertisement

NKTX Stock Latest News

Nkarta price target raised to $11 from $10 at Needham
The FlyNkarta price target raised to $11 from $10 at Needham
1d ago
NKTX
Nkarta Launches $100 Million At-the-Market Stock Offering
PremiumCompany Announcements
Nkarta Launches $100 Million At-the-Market Stock Offering
1d ago
8K
NKTX
Nkarta files $350M mixed securities shelf
PremiumThe Fly
Nkarta files $350M mixed securities shelf
2d ago
NKTX
Nkarta reports Q4 EPS (37c), consensus (29c)
PremiumThe Fly
Nkarta reports Q4 EPS (37c), consensus (29c)
2d ago
NKTX
Is NKTX a Buy, Before Earnings?
PremiumPre-Earnings
Is NKTX a Buy, Before Earnings?
10d ago
NKTX
Nkarta price target lowered to $11 from $12 at Stifel
PremiumThe FlyNkarta price target lowered to $11 from $12 at Stifel
5M ago
NKTX
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
Premium
Ratings
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
5M ago
NKTX
Nkarta Advances NKX019 Program Amid Financial Stability
Premium
Company Announcements
Nkarta Advances NKX019 Program Amid Financial Stability
5M ago
NKTX
Nkarta reports Q3 EPS (29c), consensus (30c)
PremiumThe Fly
Nkarta reports Q3 EPS (29c), consensus (30c)
5M ago
NKTX
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
PremiumCompany Announcements
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
5M ago
NKTX
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
PremiumCompany Announcements
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
5M ago
NKTX
Nkarta price target lowered to $12 from $14 at Stifel
PremiumThe Fly
Nkarta price target lowered to $12 from $14 at Stifel
8M ago
NKTX
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
PremiumRatingsPromising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
8M ago
NKTX
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
Premium
Ratings
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
8M ago
NKTX
Nkarta, Inc. Reports Q2 2025 Financial Results
Premium
Company Announcements
Nkarta, Inc. Reports Q2 2025 Financial Results
8M ago
NKTX
Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
PremiumRatings
Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
8M ago
NKTX
Nkarta reports Q2 EPS (31c), consensus (35c)
PremiumThe Fly
Nkarta reports Q2 EPS (31c), consensus (35c)
8M ago
NKTX
Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
PremiumRatings
Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
8M ago
NKTX
Nkarta price target lowered to $14 from $16 at Mizuho
PremiumThe Fly
Nkarta price target lowered to $14 from $16 at Mizuho
10M ago
NKTX
Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
PremiumThe FlyLyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
10M ago
LYEL
NKTX
Nkarta Announces Leadership Change with New CMO
Premium
Company Announcements
Nkarta Announces Leadership Change with New CMO
10M ago
8K
NKTX
Nkarta appoints Shawn Rose as CMO, head of R&D
Premium
The Fly
Nkarta appoints Shawn Rose as CMO, head of R&D
10M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >